Related Experiment Video
Updated: Aug 7, 2025
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
Published on: December 1, 2023
Organizing pneumonia following ocrelizumab use in a patient with multiple sclerosis: A case report
Nurten Aysan1, Gizem Köybaşı1, Celal Satıcı1
1Clinic of Chest Diseases, İstanbul Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, İstanbul, Türkiye.
Abstract:
Ocrelizumab is an anti-CD20 monoclonal antibody used in the treatment of primary progressive and relapsing multiple sclerosis (MS). Although cases of organizing pneumonia have been reported in association with other antiCD20 agents such as rituximab, there is insufficient data in the literature on Ocrelizumab-associated lung involvement. Herein, we present a case of organizing pneumonia in a 37-year-old female patient with multiple sclerosis following Ocrelizumab use.
Insights
Ocrelizumab, an anti-CD20 therapy for multiple sclerosis (MS), may be linked to organizing pneumonia. This case report highlights a potential adverse lung event associated with Ocrelizumab treatment.
Area of Science:
- Immunology
- Neurology
- Pulmonology
Background:
- Ocrelizumab is an anti-CD20 monoclonal antibody approved for treating multiple sclerosis (MS).
- Organizing pneumonia has been documented with other anti-CD20 therapies, like rituximab.
- Data on Ocrelizumab-induced lung complications remain limited.
Observation:
- A 37-year-old female patient with MS was treated with Ocrelizumab.
- The patient subsequently developed organizing pneumonia.
- This represents a potential adverse pulmonary event linked to Ocrelizumab therapy.
Findings:
- The case details a patient experiencing organizing pneumonia post-Ocrelizumab administration.
- This finding contributes to the limited literature on Ocrelizumab-associated lung disease.
- It suggests a need for vigilance regarding pulmonary side effects.
Implications:
- This case underscores the importance of monitoring for respiratory adverse events in patients receiving Ocrelizumab.
- Further research is warranted to elucidate the incidence and mechanisms of Ocrelizumab-associated lung injury.
- Clinicians should consider organizing pneumonia in the differential diagnosis of respiratory symptoms in MS patients on Ocrelizumab.
Related Concept Videos
01:30Pneumonia III: Complications and Assessment
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:30Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:29Pneumonia II: Pathophysiology